Interaction between regulatory T cells and mast cells via IL-9 and TGF-β production.
作者信息
Zhao Yi-Bin, Yang Shao-Hui, Shen Jie, Deng Ke, Li Qi, Wang Yu, Cui Wei, Ye Hua
机构信息
Department of Gastroenterology, Ningbo Medical Treatment Center, Lihuili Hospital, Ningbo, Zhejiang 315040, P.R. China.
出版信息
Oncol Lett. 2020 Dec;20(6):360. doi: 10.3892/ol.2020.12224. Epub 2020 Oct 14.
Research on the immunosuppression of cancer cells has attracted much attention in recent years. The present study sought to provide a new strategy for tumor immunotherapy targeting mast cells by studying the mechanisms underlying mast cell function in cancer immunosuppression. Between January 2015 and December 2017, the tumor tissues of 40 patients with gastric cancer (GC) were collected and grouped in Lihuili Hospital of Ningbo City, China. Pathological sections were prepared and an immunofluorescence assay was performed to analyze the expression of forkhead Box Protein P3 (FOXP3), tryptase, TGFβ1, TGF-βR, IL-9, IL-9R and Oxford 40 ligand (OX40L). Then, the correlations between FOXP3 and tryptase, TGFβ1 and tryptase expression, and the expression of OX40L in patients with GC with different stages were analyzed. The results revealed that high levels of mast cells were present in patients GC, and tryptase and FOXP3 expressions were positively correlated. Mast cells regulate T regulatory (reg) cells in the gastric tumor microenvironment by secreting TGFβ1. Tregs, in turn, promote the survival of mast cells in the tumor microenvironment by producing IL-9. Furthermore, OX40L expression in mast cells was significantly associated with Tumor-Node-Metastasis staging of GC. Overall, the present study reported a positive feedback system that functions through TGFβ1 and IL-9 to allow cross-talk between Tregs and mast cells. Moreover, OX40L may be a potential target for the diagnosis and treatment of GC. These results may provide a new strategy for tumor immunotherapy targeting mast cells.
相似文献
J Periodontal Res. 2018-4-6
引用本文的文献
Cell Death Discov. 2025-1-15
Heliyon. 2024-2-15
Front Immunol. 2023
Int J Mol Sci. 2022-9-17
Cancer Immunol Immunother. 2023-3
本文引用的文献
Med Sci Monit. 2019-5-13
Leukemia. 2019-2-28
Can J Gastroenterol Hepatol. 2018-6-20
Clin Rev Allergy Immunol. 2018-6
J Immunother Cancer. 2016-7-19